Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GRB2 | P62993 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489897 | 0.76 | CAPN1 (0.47) | CAPN1CTSBF2 | |
| SCHEMBL29630498 | 0.75 | CAPN1 (0.51) | CAPN1CTSBSLC6A2OPRM1OPRD1 | |
| SCHEMBL29591830 | 0.73 | CAPN1 (0.47) | CAPN1CTSBSLC6A2OPRM1OPRD1 | |
| SCHEMBL29630574 | 0.72 | CAPN1 (0.49) | CAPN1CTSBSLC6A2GRB2 | |
| SCHEMBL30580545 | 0.72 | CAPN1 (0.48) | CAPN1SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL30580544 | 0.72 | CAPN1 (0.48) | CAPN1SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL29679608 | 0.72 | CAPN1 (0.49) | CAPN1CTSBSLC6A2OPRM1OPRD1 | |
| SCHEMBL32689781 | 0.72 | CAPN1 (0.57) | CAPN1CTSBF2GRB2 | |
| SCHEMBL29630673 | 0.72 | CAPN1 (0.47) | CAPN1CTSBSLC6A2OPRM1OPRD1 | |
| SCHEMBL32689777 | 0.72 | CAPN1 (0.57) | CAPN1CTSBSLC6A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | GAA, MAN2B1, M6PR | CAPN1 1057/4885CTSB 306/4885F2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.